Tuesday, March 17, 2026

KIMES 2026: How South Korea’s Medical Device Industry is Poised for Global Expansion

KIMES 2026 showcases Korea's medical device sector, highlighting digital growth and global expansion opportunities for domestic companies.

SK hynix: A New U.S. “AI Co.” Signals the Next-Era Data Center Play—Backed by a $10B Investment

SK hynix plans to form an AI solutions company in the U.S., transforming Solidigm to enhance its role in the AI data center ecosystem.

Europe Moves to Ease Biosimilar Rules, Boosting Asia’s Biopharma Giants

EMA's new guidelines aim to simplify biosimilar development, boosting Samsung Bioepis and Celltrion in Europe's growing market.

Tag: NTSR1

SK Biofarm, FDA Approved Radioactive Method: Will it be a Revolutionary Cancer Cure with SLK 33501?

SK Biopharmaceuticals gains FDA approval for Phase 1 trials of radiopharmaceuticals SKL35501 and SKL35502, advancing cancer treatment.

Top News

- Our Sponsors Ad -

Follow us